Mark R Litzow Selected Research

Mark R Litzow Research Topics

Disease

65	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 08/2002
42	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2022 - 08/2004
40	Leukemia 01/2022 - 02/2005
32	Neoplasms (Cancer) 12/2022 - 07/2006
18	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 12/2003
16	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 11/2006
15	Philadelphia Chromosome 10/2022 - 05/2006
15	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 02/2005
12	Multiple Myeloma 12/2022 - 03/2006
12	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2020 - 01/2002
11	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 08/2006
8	Immunoglobulin Light-chain Amyloidosis 12/2010 - 11/2002
6	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 11/2021 - 11/2006
6	Thrombocytopenia (Thrombopenia) 01/2021 - 09/2005
5	Pathologic Complete Response 12/2021 - 08/2006
5	Acute Promyelocytic Leukemia 03/2017 - 07/2008
5	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2016 - 09/2005
4	Lymphoma (Lymphomas) 12/2022 - 01/2016
4	Infections 11/2017 - 05/2012
3	Residual Neoplasm 01/2022 - 04/2015
3	Bronchiolitis Obliterans Syndrome 01/2022 - 11/2013
3	Anemia 01/2021 - 08/2006
3	Cytokine Release Syndrome 01/2020 - 11/2018
3	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2020 - 11/2018
3	Venous Thromboembolism 02/2019 - 12/2015
3	Pain (Aches) 01/2019 - 06/2010
3	Mucositis 02/2017 - 09/2005
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2016 - 09/2008
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2015
2	Cytopenia 01/2022 - 01/2019
2	Systemic Mastocytosis 01/2022 - 01/2022
2	Pneumonia (Pneumonitis) 01/2021 - 09/2017
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 09/2012
2	Hemorrhage 01/2021 - 03/2017
2	Hypoxia (Hypoxemia) 10/2020 - 01/2020
2	Thrombocytosis (Thrombocythemia) 01/2020 - 05/2008
2	Erdheim-Chester Disease 11/2018 - 09/2017
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2018 - 08/2015

Drug/Important Bio-Agent (IBA)

11	blinatumomabIBA 10/2022 - 12/2011
9	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2021 - 08/2002
9	Pharmaceutical PreparationsIBA 01/2020 - 07/2008
9	Monoclonal AntibodiesIBA 01/2020 - 03/2007
7	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2006
7	Phosphotransferases (Kinase)IBA 12/2021 - 01/2002
7	Imatinib Mesylate (Gleevec)FDA Link 12/2016 - 01/2002
6	Tyrosine Kinase InhibitorsIBA 12/2018 - 10/2009
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2015 - 03/2006
5	venetoclaxIBA 01/2022 - 01/2020
5	Biomarkers (Surrogate Marker)IBA 10/2021 - 05/2012
5	Chimeric Antigen ReceptorsIBA 10/2020 - 01/2013
5	Proteins (Proteins, Gene)FDA Link 11/2019 - 04/2006
5	AntigensIBA 01/2019 - 03/2007
5	Rituximab (Mabthera)FDA Link 03/2016 - 12/2011
4	Lenalidomide (CC 5013)FDA Link 01/2021 - 08/2006
4	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 01/2018
4	Immunoconjugates (Immunoconjugate)IBA 10/2020 - 06/2014
4	AnthracyclinesIBA 11/2019 - 09/2009
4	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2018 - 05/2011
4	Tyrosine (L-Tyrosine)FDA Link 02/2016 - 03/2007
3	Melphalan (Alkeran)FDA LinkGeneric 12/2022 - 10/2008
3	midostaurinIBA 01/2022 - 12/2020
3	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 04/2016
3	alvocidib (flavopiridol)IBA 10/2021 - 09/2015
3	Mitoxantrone (Novantrone)FDA LinkGeneric 10/2021 - 09/2015
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2021 - 02/2017
3	Inotuzumab OzogamicinIBA 01/2021 - 06/2014
3	CalicheamicinsIBA 01/2020 - 11/2014
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 11/2018
2	CreatinineIBA 12/2022 - 03/2016
2	Calcineurin InhibitorsIBA 01/2022 - 01/2019
2	Tacrolimus (Prograf)FDA LinkGeneric 01/2022 - 01/2019
2	ruxolitinibIBA 01/2022 - 10/2011
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2020
2	Decitabine FDA Link 01/2021 - 07/2009
2	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 08/2017
2	Erythropoietin Receptors (Erythropoietin Receptor)IBA 01/2021 - 02/2016
2	Hemoglobins (Hemoglobin)IBA 01/2021 - 08/2006
2	Erythropoietin FDA Link 01/2021 - 02/2016
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020 - 08/2012
2	Histones (Histone)IBA 11/2019 - 02/2017
2	tisagenlecleucelIBA 11/2019 - 01/2019
2	N 30IBA 01/2019 - 03/2016
2	Biological ProductsIBA 11/2018 - 10/2017
2	nilotinib FDA Link 01/2018 - 10/2017
2	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 01/2018 - 04/2015

Therapy/Procedure

76	Therapeutics 01/2022 - 08/2002
33	Drug Therapy (Chemotherapy) 10/2022 - 11/2002
31	Cell Transplantation 01/2022 - 02/2007
24	Hematopoietic Stem Cell Transplantation 12/2022 - 02/2005
20	Transplantation 11/2019 - 06/2002
17	Stem Cell Transplantation 01/2020 - 11/2002
12	Homologous Transplantation 01/2019 - 04/2006
8	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 08/2008 - 06/2002
7	Induction Chemotherapy 10/2022 - 01/2005
7	Immunotherapy 10/2020 - 01/2014
5	Autologous Transplantation 12/2022 - 02/2006
3	Consolidation Chemotherapy 01/2020 - 02/2006
3	Bone Marrow Transplantation (Transplantation, Bone Marrow) 02/2005 - 12/2003
2	Artificial Respiration (Mechanical Ventilation) 01/2021 - 06/2003
2	Photopheresis 01/2020 - 01/2018